United-Guardian Reports Increased Third Quarter Earnings

Rhea-AI Summary

United-Guardian reported increased financial results for Q3 and the first nine months of 2024. Nine-month sales grew from $8.28M to $9.71M, with net income rising from $1.84M ($0.40/share) to $2.75M ($0.60/share). Q3 sales remained stable at $3.06M, while net income increased from $627K ($0.14/share) to $865K ($0.19/share). Cosmetic ingredients sales rose 8% in Q3 and 68% in the first nine months. Medical lubricants saw a 2% Q3 decrease but 4% nine-month growth. Pharmaceutical sales declined 6% in Q3 and 11% over nine months due to a Renacidin® supply disruption.

Positive

• Nine-month revenue increased 17.2% to $9.71M
• Net income grew 49% to $2.75M for nine months
• EPS increased 50% to $0.60 for nine months
• Cosmetic ingredients sales surged 68% in first nine months
• Q3 net income improved 38% to $865K

Negative

• Pharmaceutical sales declined 11% over nine months
• Medical lubricants decreased 2% in Q3
• Ongoing supply disruption issues with Renacidin product

News Market Reaction

-12.06%

1 alert

-12.06% News Effect

On the day this news was published, UG declined 12.06%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

HAUPPAUGE, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2024. Sales for the nine-month period ended September 30^th increased from $8,278,141 in 2023 to $9,705,262 in 2024 and net income increased from $1,843,931 ($0.40 per share) to $2,747,151 ($0.60 per share) for the same period. The third quarter remained steady with sales of $3,057,518 in 2023 and $3,060,113 in 2024, while net income increased from $626,756 ($0.14 per share) to $865,484 ($0.19 per share).

Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that sales and earnings increased in the third quarter and for the first nine months of 2024 compared with the same periods in 2023. We continue to have strong sales of our cosmetic ingredients, which increased by 8% in the third quarter and 68% in the first nine months of 2024. This overall increase was primarily attributable to sales to our largest cosmetic distributor. Sales of medical lubricants decreased by 2% in the third quarter, which was attributed to normal fluctuation in order patterns, while increasing by 4% in the first nine months of 2024, compared with the same periods in 2023. Pharmaceutical product sales continue to recover from a supply disruption that occurred at our contract manufacturer for Renacidin^®, our most important pharmaceutical product, late last year. Sales of pharmaceuticals decreased by 6% in the third quarter and 11% for the nine-month period. We expect our sales will continue to increase as we recover from the shutdown that limited our supply of Renacidin.”

United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.

Contact: Donna Vigilante
(631) 273-0900
dvigilante@u-g.com

NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

Financial Results for the Three and Nine Months Ended September 30, 2024 and 2023 STATEMENTS OF INCOME (unaudited)
		THREE MONTHS ENDED SEPTEMBER 30,					NINE MONTHS ENDED SEPTEMBER 30,
		2024			2023			2024			2023
Net sales	$	3,060,113		$	3,057,518		$	9,705,262		$	8,278,141
Costs and expenses:
Cost of sales		1,408,866			1,749,041			4,526,446			4,272,043
Operating expenses		591,047			488,464			1,762,689			1,580,503
Research and development expense		111,072			98,141			325,714			353,829
Total costs and expenses		2,110,985			2,335,646			6,614,849			6,206,375
Income from operations		949,128			721,872			3,090,413			2,071,766
Other Income (expense):
Investment income		99,934			79,682			298,014			182,264
Net gain (loss) on marketable securities		47,223			(14,357	)		79,218			65,823
Total other income		147,157			65,325			377,232			248,087
Income before provision for income taxes		1,096,285			787,197			3,467,645			2,319,853
Provision for income taxes		230,801			160,441			720,494			475,922
Net income	$	865,484		$	626,756		$	2,747,151		$	1,843,931
Earnings per common share (Basic and Diluted)	$	0.19		$	0.14		$	0.60		$	0.40
Weighted average shares – basic and diluted		4,594,319			4,594,319			4,594,319			4,594,319

FAQ

What was United-Guardian's (UG) revenue for Q3 2024?

United-Guardian's revenue for Q3 2024 was $3.06 million, relatively flat compared to $3.06 million in Q3 2023.

How much did United-Guardian's (UG) EPS increase in Q3 2024?

United-Guardian's EPS increased to $0.19 in Q3 2024, up from $0.14 in Q3 2023.

What was the growth rate of United-Guardian's (UG) cosmetic ingredients sales in 2024?

United-Guardian's cosmetic ingredients sales increased by 8% in Q3 and 68% in the first nine months of 2024.

Why did United-Guardian's (UG) pharmaceutical sales decline in 2024?

Pharmaceutical sales declined due to a supply disruption at the contract manufacturer for Renacidin, decreasing 6% in Q3 and 11% for the nine-month period.